Benchmark International 
Archives
Think healthcare M&A is on its way out in 2016? Think again. Following the surprising failure in April of the deal between Pfizer and Allergan, many analysts have raised concerns that a similar pattern will ensue within healthcare deal making. While the collapse of the $160bn deal was unexpected, and brought total value of abandoned deals this year to its highest since the eve of the financial crisis at $376bn, industry experts… Read More